Mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene have been shown to predispose to pituitary adenoma predisposition, a condition characterized by growth hormone (GH)-secreting pituitary tumors. To study AIP-mediated tumorigenesis, we generated an Aip mouse model. Heterozygous mice developed normally but were prone to pituitary adenomas, in particular to those secreting GH. A complete loss of AIP was detected in these lesions, and full penetrance was reached at the age of 15 months. No excess of any other tumor type was found. Ki-67 analysis indicated that Aip-deficient tumors have higher proliferation rates compared with Aip-proficient tumors, suggesting a more aggressive disease. Similar to human AIP-deficient pituitary adenomas, immunohistochemical studies showed that expression of aryl hydrocarbon receptor nuclear translocator 1 or 2 (ARNT or ARNT2) protein was lost in the mouse tumors, suggesting that mechanisms of AIP-related tumorigenesis involve aberrant ARNT function. The Aip ؉/؊ mouse appears to be an excellent model for the respective human disease phenotype. This model constitutes a tool to further study AIPassociated pituitary tumorigenesis and may be potentially valuable in efforts to develop therapeutic strategies to treat pituitary adenomas. Pituitary adenomas are common, benign, monoclonal neoplasms of the anterior pituitary gland. They account for approximately 15% of intracranial tumors. Approximately two thirds produce pituitary hormones in excess; among these, prolactin (PRL) and growth hormone (GH)-oversecreting adenomas are the most common. The significant morbidity associated with these lesions arises from the adverse effects of the hypersecretion, such as acromegaly or gigantism in the case of GH secreting adenomas, and/or local compressive effects.
1Mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene have been identified as an underlying cause in human pituitary adenoma predisposition (OMIM 102200), characterized mainly by GH secreting adenomas (somatotropinomas), although susceptibility to PRL (prolactinomas), adrenocorticotropic hormone (ACTH), and nonsecreting adenomas is also part of the disease phenotype. [2][3][4][5] So far AIP mutations have not been associated with any other tumor types.6 -8 Typically, pituitary adenoma predisposition patients have a young age at disease onset but do not necessarily display a strong family history of pituitary adenomas. AIP mutation positive tumors seem to be larger and may have a worse response to somatostatin analogs as compared to sporadic tumors. 4,5,9 Inactivating germline mutations, loss of the normal allele in tumors, as well as recent functional evidence implicate the tumor suppressor role of the AIP gene. 2,5,10 Many of the proteins known to interact with AIP can be linked to tumorigenesis. The best known function of AIP is to stabilize aryl hydrocarbon receptor (AHR) (also known The American Journal of Pathology, Vol. 177, No. 4, October 2010 Copyright © American Society for Investigative P...